Study of Profound's prostate cancer device gets green light

09/19/2013 | MassDevice.com (Boston)

The FDA has granted Profound Medical investigational device exemption approval to conduct a clinical study of its device that uses real-time MRI guidance and thermal ultrasound to treat patients with localized prostate cancer. The Canadian company plans to start patient enrollment in the trial in late 2013.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN